1. U.S. Emerging Prostate Cancer Therapeutics Markets Development of New Products with Fewer Adverse Patient Reactions Drives Market "Promoting a product based on superior anti-tumor activity, with less toxicity and without compromising the quality of life of patients, is going to be key to the success of any newly approved product." Pharmaceuticals Analyst Team Frost & Sullivan

2. Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analytical insights into current topics and emerging applications in the prostate cancer therapeutics market Market-sizing and competitive analysis Market forecasts and opportunity analyses Quarterly assessments End-user analysis Key Features

3. Coverage: The United States Proven methodology using extensive primary and secondary data as well as research Focused information and strategies that cover business and technology issues Credible data and analyses that highlight industry dynamics Precise strategies to help you create winning business plans What We Offer

4. Current Market Participants Find out where you stand in comparison with the competitors Assess current and future drivers as well as restraints Determine and exploit new market share opportunities New Entrants Analyze the associated challenges Calculate timescales for strategy implementation Position yourself to capitalize on the unmet needs of the market Investment Community Analyze long-term strategies of companies Determine which participants will outperform the competition Assess the attractiveness of investing in the market Who Will Benefit?

5. Aeterna Laboratories, Inc. Alfacell Corp. Amgen, Inc. Aphton Corp. AstraZeneca Pharmaceuticals LP Atrix Laboratories, Inc. Aventis Pharmaceuticals, Inc. Bone Care International Bristol-Myers Squibb, Inc. Calydon, Inc. Celgene Corp. Cell Genesys, Inc. Cell Pathways, Inc. Cell Therapeutics, Inc. Cephalon, Inc. Cytran, Inc. Dendreon Corp. Eli Lilly and Co. EntreMed, Inc. Epic Therapeutics, Inc. Key Market Participants Genaera Corp. Genentech, Inc. Genta, Inc. ILEX Oncology, Inc. Medarex, Inc. MGI Pharma, Inc. Myriad Genetics, Inc Northwest Biotherapeutics, Inc. Novartis Pharmaceuticals Corp. Pharmacia Corp. Praecis Pharmaceuticals Protarga, Inc. Seattle Genetics, Inc. Shire Pharmaceutical Group Plc TAP Pharmaceutical Products, Inc. Therion Biologics Corp. Titan Pharmaceuticals, Inc. Vical, Inc. YM BioSciences, Inc.

6. Call toll free 877 G O F ROST (877.463.7876) Fax toll free 888.690.3329 E-mail myfrost@frost.com Visit www.frost.com For More Information